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Early-life infections with persistent Epstein–Barr virus (EBV) and cytomegalovirus (CMV) 
are delayed in affluent countries, probably due to alterations in early environmental expo-
sures, such as maternal age, siblings, and day-care attendance. We have previously 
reported that the timing of EBV and CMV contraction is related both to allergic sensitization 
and changes in functional competence of immune cells, while the presence/absence of 
lactobacilli [Lactobacillus (L.) casei, L. paracasei, and L. rhamnosus] or Staphylococcus 
(S.) aureus in feces is related to the risk for allergy. Here, we used the same prospective 
longitudinal birth cohort of children to investigate early-life environmental exposures and 
their influence on EBV and CMV contraction over time. Since gut microbes also belong 
to this category of early exposures, we investigated their association with herpesvirus 
contraction. Our results show that these two viruses are acquired with different kinetics 
and that EBV and CMV seroprevalence at 10 years of age was 47 and 57%, respectively. 
We also observed that a delayed EBV or CMV infection was associated with older mater-
nal age [time ratio (TR) 1.14, 95% confidence interval (CI) 1.07–1.21, Padj < 0.001 and 
TR 1.09, CI 1.03–1.16, Padj = 0.008, respectively]. Further, we present the novel finding 
that S. aureus colonization reduced the time to CMV acquisition (TR 0.21, CI 0.06–0.78, 
Padj = 0.02). Together, these findings suggest that there is a relationship between timing 
of herpesvirus acquisition and early-life immune modulating exposures, which interest-
ingly also includes the early infant gut microbiota.
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inTrODUcTiOn
Epstein–Barr virus (EBV) and cytomegalovirus (CMV) are herpesviruses commonly contracted 
during infancy, and they are prevalent in the human population worldwide. They belong to what is 
referred to as the human virome or virobiota – a collection of both eukaryotic and prokaryotic viruses 
are found in humans (1–3). The majority of adults (over 90%) are considered to be seropositive for 
TaBle 1 | Demographics of study population.
characteristics Total
children, n 281
Maternal age at delivery
Years, median (min–max) 31 (21–44)
child gendera
Boys, n (%) 140 (49.8)
Girls, n (%) 139 (49.2)
Delivery mode
Vaginal, n (%) 238 (84.7)
C-section, n (%) 43 (15.3)
exclusive breastfeedingb
Months, median (range) 4 (0–10)
Day-care startc
Months, median (min–max) 18 (12–26)
siblingsd
Number, median (min–max) 0 (0–5)
Data missing from an = 2, bn = 1, cn = 17, and dn = 35 individuals.
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EBV (4, 5), and the transmission commonly occurs via saliva (6). 
In early childhood, primary infection with EBV is commonly 
mild or even asymptomatic, while during adolescence or in 
adults, the EBV infection more often manifests as acute infec-
tious mononucleosis (5, 7). In relation to CMV, between 60 and 
90% of adults are considered to be seropositive, however not 
without substantial geographic variation that is associated with 
socioeconomic status (8). CMV transmission occurs through 
various body fluids including maternal genital secretions at birth 
and breast-milk, as well as via urine from children and adults (9, 
10). EBV can infect B-lymphocytes and epithelial cells (11), while 
myeloid cells are the main CMV reservoirs (12). After primary 
infection, EBV and CMV establish latency and persist for life. 
Both viruses are then chronically or intermittently shed for the 
lifetime of the host, and their re-activation is under tight immu-
nological control. Still, herpesviruses can be a serious threat to the 
immunocompromised host (2, 4).
There has been a marked change in life-style and environ-
mental exposures in many parts of the world during the last 
decades, which has been accompanied by a steep increase of 
immune-mediated disorders, such as allergy and asthma. Also, 
the higher sanitation standards of westernized countries and 
prompt antibiotic availability are believed to cause alterations in 
our exposure to beneficial microbes, which may be disadvanta-
geous to immune development and maturation (2, 13–15). Using 
a well-characterized prospective longitudinal birth cohort, we 
have previously reported that EBV and CMV seropositivity 
relates both to allergic sensitization (16, 17) and modulated 
immune function in children (18–20). The presence of early-
life microbiota was also investigated in this cohort, where a 
group of lactobacilli [Lactobacillus (L.) casei, L. paracasei, and 
L. rhamnosus] and Staphylococcus (S.) aureus DNA were related 
to opposite allergic profiles at 5 years of age (21). As the order 
and timing of colonization with these microbial agents has been 
suggested to affect functional capacity of the infant immune 
system (15–21), herein we investigated the seropositivity for 
EBV and CMV at four time points up to 10 years of age in the 
same children and assessed the possible association between 
environmental exposures, including gut microbiota coloniza-
tion following birth and the acquisition of herpesviruses over 
a 10-year period.
MaTerials anD MeThODs
ethical statement
The study was approved by the Human Ethics Committee at 
Huddinge University Hospital, Stockholm (Dnr 75/97, 331/02, 
2007/858-31/2), and the parents provided their informed verbal 
consent. No written documentation of the participants informed 
approval was required, which was agreed to by the Human Ethics 
Committee and was according to the regulations at the time of the 
initiation of the study.
subjects
Our study included subjects from a prospective birth cohort 
of 281 children born between 1997 and 2000 in the Stockholm 
area (16, 17, 21). The demographic information from the study 
population is presented in Table 1. Two thirds of the children 
had parental allergic heredity (either from the mother or from 
both parents), while the remaining third had no allergic heredity. 
The parents were asked at the maternity wards to participate with 
their child in the study and were given the possibility of calling 
an experienced pediatric nurse with questions about their child 
at any time. Data collection on exposures (breastfeeding, day 
care, etc.) was described in detail previously (16, 17, 21).
serological Methods for Determinations 
of eBV and cMV infections
Venous blood samples were drawn at several time points in order 
to evaluate the presence of IgG antibodies against EBV and CMV. 
For the presence of IgG antibodies against both EBV and CMV 
at 1, 2, and 5 years, the protocol was described previously (16, 
17). To determine the herpesvirus serostatus at 10 years of age, 
IgG against EBV viral-capsid antigen as well as EBV nuclear 
antigen-1 was analyzed via immunofluorescence assays (22), and 
IgG against CMV was determined with an in-house CMV-IgG 
ELISA according to a protocol described elsewhere (23). Serum 
samples were analyzed in dilutions of 1/50, 1/100, and 1/1000. 
An absorbance value of 0.20 was taken as a positive reaction. 
Positivity in dilution 1/50, but not in 1/100, was considered as 
gray zone.
lactobacilli and Staphylococcus (S.) 
aureus Detection in Fecal samples
The presence and the relative frequencies (expressed as %) of DNA 
of commensals were detected previously by us (21, 24) through 
real-time PCR in fecal samples of the children in the cohort at 1 
and 2 weeks and at 1 and 2 months of age, providing that they 
were vaginally delivered, fully breastfed for at least 3  months, 
received no antibiotics treatment, and had fecal samples avail-
able for testing. Different species of Bifidobacterium, S. aureus, 
a group of lactobacilli [Lactobacillus (L.) casei, L. paracasei, and 
L. rhamnosus], and Clostridium difficile were evaluated on those 
studies (21, 24). In this present study, however, we focused our 
analyses on the lactobacilli group and S. aureus only, due to their 
TaBle 2 | herpesvirus seroprevalence during the first 10 years of life in 
children born in stockholm.
age
children 1 yeara 2 yearsb 5 yearsc 10 yearsd
EBV seropositive (%) 13.0 18.9 38.3 47.1
CMV seropositive (%) 7.8 40.0 57.4 57.6
A total of n = 281 individuals were followed from birth to 10 years of age. Plasma was 
available for determination of EBV and CMV seropositivity from an = 115, bn = 241, 
cn = 215, and dn = 207 children. Children with inconclusive samples for either EBV 
(n = 3) or CMV (n = 9) were excluded from all time points.
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notable opposite associations with the immune profile and allergy 
prevalence during infancy and childhood (21, 24–27).
statistics
Association analyses between infection (EBV/CMV) and 
explanatory variables were performed separately for each age 
group since some children did not have complete data from all 
4 years. Associations were estimated as odds ratios (ORs) using 
univariate logistic regression models, with EBV (0/1) or CMV 
(0/1) as outcome. In an effort to use the information from all four 
time points in one analysis, an interval censored survival analysis 
was also performed. Here, the input data for each child were 
the time interval when the infection occurred [e.g., a child not 
infected at year 2 and infected at year 4 get a time interval of (2, 
4), and a child uninfected during the four time points get a time 
interval of >10]. Such time intervals were, despite missing data, 
possible to decide for the majority of children. A two-parameter 
gamma distribution, parameterized as an accelerated failure time 
model, was used to model the infection times. The effect of an 
explanatory variable on the infection time is manifested as a time 
ratio (TR) and shows how an explanatory variable speeds up or 
delays the expected infection time. ORs and TRs were reported 
with a corresponding 95% confidence interval (CI), and a P-value 
for a test of the hypothesis that the OR/TR is equal to 1. Due to the 
explorative nature of testing associations between EBV and CMV 
infections and early-life exposures (Table 3), results were adjusted 
for multiple analyses according to the Bonferroni correction, 
whereby P <  0.01 was considered as statistically significant. In 
the remaining analyses, statistical significance was declared when 
P ≤ 0.05. The statistical computations were performed with Stata 
13 (StataCorp LP, USA).
resUlTs
eBV and cMV seroprevalence during the 
First 10 Years of life
The seroprevalence of EBV gradually increased up to 10 years of 
age from 13% at 1 year, 18.9% at 2 years, 38.3% at 5 years, and up 
to 47.1% at 10 years of age. In contrast, for CMV, a rapid increase 
between 1 and 2 and a clear plateau between 5 and 10 years of 
age was observed, where 8% of the children were positive at 
1 year, 40.0% at 2 years, 57.4% at 5 years, and 57.6% at 10 years 
of age (Table  2; Figure  1A). Upon subdividing the children 
into three groups based on the presence of EBV or CMV alone 
or co-infection with both viruses, we observed that 8.2% were 
positive for both viruses at 2 years, 20.9% at 5 years, and 26.9% 
at 10 years of age. None of the children at 1 year were co-infected 
with CMV and EBV (Figure 1B).
eBV and cMV acquisition is associated 
with Maternal age
In order to establish if there were any associations between EBV 
or CMV acquisition and early-life environmental exposures, 
the time to infection with these viruses was investigated as the 
outcome (Table 3). We found a statistically significant increase in 
time to EBV infection (i.e., delayed infection) per year increase 
of the maternal age (TR 1.14, CI 1.07–1.21, P <  0.001), which 
was sustained following adjustment for all included variables 
(Table 3). Following exclusion of data from 1-year-old time point, 
the following adjusted P-values were generated for EBV: <0.001 
(maternal age), 0.73 (delivery mode), 0.20 (day-care start age), 
0.32 (exclusive breastfeeding), and 0.92 (older siblings, data not 
shown). When the time to infection with CMV was investigated 
as the outcome (Table  3), a delay in time to CMV infection 
per year increase of the mother’s age (TR 1.09, CI 1.03–1.16, 
P = 0.004) was observed, which was statistically significant after 
adjustment for all included variables. Following exclusion of data 
from 1-year-old time point, the following adjusted P-values were 
generated for CMV: <0.008 (maternal age), 0.59 (delivery mode), 
0.90 (day-care start age), 0.91 (exclusive breastfeeding), and 0.09 
(older siblings, data not shown).
When evaluating associations for each age separately, the 
odds of EBV infection at 2, 5, and 10 years of age decreased with 
increased maternal age at time of birth, i.e., EBV infection was 
delayed in children with older mothers (Table S1 in Supplementary 
Material). When evaluating the associations between maternal 
age and likelihood of CMV infection for each age separately, how-
ever, no statistically significant associations were found (Table S2 
in Supplementary Material). The odds of being CMV infected at 
2 years of age was, however, low when the number of older sib-
lings increased (Table S2 in Supplementary Material). We did not 
observe any notable differences in socioeconomic status between 
the group of children that were infected with herpesviruses early 
(i.e., at age 2 years) and those who remained seronegative at the 
age of 10 years (Figure S1 in Supplementary Material).
Timing of cMV acquisition is associated 
with early-life gut Microbes
Studies in mice reveal that the gut microbiota can influence the 
susceptibility to viral infections (28, 29), but whether this is true 
also in humans is not known. We investigated the associations 
between EBV and CMV and the presence of two different types of 
bacteria commonly present in the neonatal gut but with opposite 
effects on immune function – a group of lactobacilli (L. casei, L. 
paracasei, and L. rhamnosus) and S. aureus (25, 27). There were 
no statistically significant associations between early colonization 
with lactobacilli and EBV or CMV infections when investigating 
time of infection as the outcome (Table 4). Interestingly, S. aureus 
colonization did not seem to influence the time to EBV infection, 
while it was significantly associated with earlier CMV infection 
FigUre 1 | seropositivity of cMV and eBV. (a) Total CMV and total EBV seropositivity. (B) Single CMV seropositivity, single EBV seropositivity, and co-infection 
with EBV and CMV. Y: years.
TaBle 3 | associations between early-life exposures and eBV and cMV seropositivity.a
Variableb
eBV cMV
N Tr (95% ci) P Padj N Tr (95% ci) P Padj
Maternal age 265 1.14 (1.07–1.21) <0.001 <0.001 265 1.09 (1.03–1.16) 0.004 0.008
Delivery mode 265 0.89 (0.45–1.75) 0.74 0.79 265 0.82 (0.41–1.64) 0.57 0.51
Day-care start age 228 1.09 (1.00–1.18) 0.05 0.20 228 1.03 (0.94–1.13) 0.55 0.80
Exclusive breastfeeding 265 1.02 (0.87–1.19) 0.82 0.43 265 0.97 (0.83–1.13) 0.67 0.86
Older siblings 246 1.13 (0.81–1.56) 0.48 0.97 246 1.56 (1.07–2.26) 0.02 0.06
aThe effect of an explanatory variable on the infection time manifested as a time ratio (TR); N: number of individuals with data available for each given variable; CI: confidence interval 
range; Padj: P-values adjusted for allb included variables. Bolded P-values: statistically significant following Bonferroni correction.
4
Carvalho-Queiroz et al. Early Microbiota and Herpesvirus Seropositivity
Frontiers in Pediatrics | www.frontiersin.org August 2016 | Volume 4 | Article 93
if children were colonized with S. aureus on two or more occa-
sions (Table 4, TR 0.21, CI 0.06–0.78, P = 0.02), which sustained 
following adjustment for maternal age (Padj  =  0.02, Table  4). 
Following exclusion of data from 1-year-old time point, S. aureus 
colonization was still associated with earlier CMV infection if 
children were colonized with S. aureus on two or more occasions 
(n = 65, TR 0.12, CI 0.01–1.01, Padj = 0.05).
No statistically significant differences with regard to mater-
nal age, day-care starting age, or number of siblings among 
the groups assessed for colonization with the Lactobacilli or 
S. aureus were found (data not shown). Further, on analyzing 
association between early gut colonization and herpesvirus 
infection in relation to each age group separately (Tables S3 
and S4 in Supplementary Material), S. aureus colonization was 
related to increased odds of CMV seropositivity at 5 and 10 years 
of age (OR 3.16, CI 1.00–10.00, Padj <  0.05 and OR 4.11, CI 
1.20–14.13, Padj = 0.02, respectively; Table S4 in Supplementary 
Material). Following exclusion of data from 1-year-old time 
point, S. aureus colonization was still associated with increased 
odds of CMV seropositivity at 5 and 10 years of age (n = 56, OR 
3.11, CI 0.98–9.87, Padj = 0.05 and n = 55, OR 4.31, CI 1.22–15.18, 
Padj = 0.02, respectively).
DiscUssiOn
In our study, we took advantage of a longitudinal prospective birth 
cohort of children followed until 10 years of age, thereby providing 
a unique opportunity to investigate early environmental exposures 
TaBle 4 | association between gut microbes and time to eBV and cMV acquisition.a
Detection after birth
eBV cMV
N Tr (95% ci) P Padj N Tr (95% ci) P Padj
lactobacilli
1 week, presence 68 1.15 (0.29–4.49) 0.84 0.98 68 3.1 (0.77–12.47) 0.11 0.10
2 weeks, presence 66 0.62 (0.18–2.12) 0.44 0.24 66 1.45 (0.49–4.27) 0.50 0.46
1 month, presence 63 0.68 (0.21–2.14) 0.50 0.32 63 2.00 (0.61–6.58) 0.25 0.25
2 months, presence 65 2.01 (0.55–7.31) 0.29 0.11 65 1.73 (0.57–5.28) 0.33 0.33
Occasions, 2 or more 67 1.56 (0.44–5.49) 0.49 0.76 67 1.83 (0.60–5.58) 0.29 0.27
S. aureus
1 week, presence 68 1.55 (0.46–5.20) 0.48 0.42 68 0.39 (0.12, 1.25) 0.11 0.11
2 weeks, presence 66 0.44 (0.11–1.81) 0.25 0.29 66 0.21 (0.06, 0.78) 0.02 0.02
1 month, presence 63 0.97 (0.26–3.56) 0.96 0.69 63 0.36 (0.09, 1.47) 0.15 0.16
2 months, presence 65 0.87 (0.23–3.29) 0.83 0.77 65 0.57 (0.16, 1.98) 0.37 0.38
Occasions, 2 or more 67 1.02 (0.28–3.70) 0.97 0.50 67 0.35 (0.10, 1.21) 0.10 0.10
aAll subjects were vaginally delivered, fully breastfed for a minimum of 3 months, and did not undergo any antibiotics treatment at the time of fecal sampling. The effect of an 
explanatory variable on the infection time manifested as a time ratio (TR); N: number of individuals with data available for each given variable; CI: confidence interval range; Padj:  
P-values adjusted for mother’s age. Bolded P-values: statistically significant.
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and their possible influence on EBV and CMV infections over 
time. Our results show that these two viruses are acquired with 
different kinetics and that the EBV and CMV seroprevalence at 
age of 10 years was 47 and 57%, respectively. When relating these 
findings to maternal age as well as to early exposures such as 
duration of breastfeeding, siblings, and day-care attendance, we 
observed that a delayed EBV and CMV infection was associated 
with older maternal age. Further, we found associations between 
the early-life gut colonization and modulation of odds to contract 
CMV infection as S. aureus colonization early in life reduced the 
time to CMV acquisition.
Herpesvirus infections are delayed in affluent compared to 
developing countries (30). In line with these observations, we 
found relatively low herpesvirus seroprevalence in our study 
cohort of Swedish children, with around 57% CMV and 47.1% 
EBV seropositive children at 10 years of age. The prevalence of 
congenital CMV, which is observed when the virus is transmitted 
to the fetus upon primary infection, reactivation, or re-infection, 
has been shown to occur in 0.2–2% of pregnant women in 
westernized countries [reviewed in Ref. (31)], arguing against a 
major influence on our results. Also, to avoid misinterpretation 
of the seropositivity and/or infection kinetics due to interference 
with maternal herpesvirus-specific antibodies in the circulation 
of newborn children, we choose to exclude data concerning 
seropositivity at 6 months of age. In addition, similar P-values we 
generated when analyses were performed with or without EBV 
and CMV serostatus data from 1-year olds. When comparing the 
kinetics between EBV and CMV infections, our results showed 
that CMV was often acquired earlier in life than EBV, and CMV 
was also more common in our study population at 10 years of 
age than EBV. In agreement with our observations of the kinetics 
of the time of contracting EBV and CMV, which was most rapid 
during the first 2 years of life for both viruses, children are more 
likely to be exposed to these herpesviruses through their contact 
with family and day-care members early in life (9). The reason for 
CMV being the most prevalent of these two viruses at 2–10 years 
of age is not clear but may be in part connected to the maturation 
and expansion of virus-specific memory cells. In agreement with 
this, we have shown that CMV seropositive infants who are EBV 
naive have a large population of IFN-γ-producing T cells (19, 
20), the presence of which associates with the inhibition of B-cell 
transformation upon in  vitro EBV infection of B cells derived 
from children in this cohort (20). However, other factors such as 
differences in the prevalence of herpesviruses among the parents, 
transmission kinetics, the infectivity, and/or the reactivation 
potential of each virus may also play a role.
We also found that a delay in both EBV and CMV infections 
was related to older maternal age at the time of birth. Such asso-
ciations with maternal age have been previously described for 
CMV, where the infection was more frequent in children whose 
mothers were 25 years or younger – which was suggested to be 
linked to higher CMV viral shedding in younger mothers (32). 
Alternatively, we can speculate that social and behavioral changes 
and/or altered hygiene practices with increased maternal age may 
also play a role in delayed infection pattern with herpesviruses. 
Whether other coupling factors other than those the results were 
adjusted for could explain this finding may be possible. Yet, socio-
economic inequality, which is a central risk factor for microbial 
infections, does not explain our findings since children that 
became seropositive for either herpesviruses at 2 years of age had 
similar socioeconomic status to those remaining seronegative at 
10 years of age.
The microbiota plays an integral role in supplying important 
signals for immune priming, immune development, and affecting 
the susceptibility to pathogens (33, 34). The interactions between 
our commensal microbiota and bacterial pathogens, especially in 
early life, have been extensively pursued during the past decades 
(14, 35, 36), while the interplay between viruses and commensals 
has only recently begun to be appreciated (2, 3, 33, 37). Indeed, the 
influence of microbiota on viral infections can have a dual role: 
it can culminate in protection of the host against the virus and in 
promotion of the viral establishment (34, 37, 38). In our study, we 
investigated the presence of lactobacilli or S. aureus DNA in fecal 
samples as proxies for early-life microbiota, since we have earlier 
found in our cohort that these are linked to immunomodulatory 
properties during early childhood (21, 25). Our results indicate 
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that an early S. aureus colonization decreased the time to CMV 
acquisition. This finding is intriguing in relation to earlier obser-
vations on increased risk of allergy in infants who were CMV 
infected but EBV naive (16). How microbes in the gut condition 
the host resistance against herpesviruses in humans remains to 
be addressed. Bleotu et  al. found that infection of HeLa cells 
with herpes simplex virus (HSV) in the presence of inactivated 
S. aureus induced TNF, IL-6, and IL-8 cytokines, and suggested 
that bacterial antigens could contribute to altered herpesvirus cell 
binding and multiplication rate in vitro (39).
Some limitations should be acknowledged. As different spe-
cies and/or strains of commensals can play a different role, a full 
microbiota analysis could bring more information about their 
composition and possible association with CMV, EBV, and other 
viruses, especially in a larger cohort of children. Also, it could be 
argued that the statistical model used here may lose stability due 
to the size of data sets. Nonetheless, using TR as our read-out 
enabled us to include additional subjects with occasional missing 
data. Further, interactions with viruses and bacteria could shape 
immune responses and have previously been described for better 
(40) or for worse (41, 42) but mainly in animal models. Therefore, 
despite the limited number of children and commensal species 
investigated here, our study is unique with its longitudinal 
approach with data sets following birth to 10 years of age and is 
among the first to describe an association between early infant 
gut colonization and timing of CMV contraction. Mechanisms 
behind the contribution of cross talk between herpesviruses and 
the gut microbiota for the development of an allergic phenotype 
remain yet unclear and should be elucidated in future studies.
In conclusion, we report that both EBV and CMV seropositiv-
ity occurs relatively late in Swedish children and that maternal age 
seems to be an important factor for the odds of acquiring EBV 
or CMV infection. Further, our data suggest that a connection 
between harboring certain gut species and tuning of host reactivity 
against herpesviruses may exist, which could ultimately influence 
maturation and functional competence of the immune system 
and potentially also allergic sensitization during childhood.
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